Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
05:41pm, Friday, 11'th Apr 2025
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
04:01pm, Friday, 11'th Apr 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune
US FDA approves syringe version of Argenx's immune disorder drug
05:59pm, Thursday, 10'th Apr 2025
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option o
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term
Stock Picks From Seeking Alpha's March 2025 New Analysts
02:30pm, Friday, 04'th Apr 2025
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
12:45pm, Monday, 31'st Mar 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is t
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?
10:35am, Monday, 17'th Mar 2025
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
03:17pm, Thursday, 27'th Feb 2025
argenx SE (NASDAQ:ARGX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hau
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
11:58am, Thursday, 27'th Feb 2025
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and th
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
01:00am, Thursday, 27'th Feb 2025
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA
argenx to Present at TD Cowen 45th Annual Healthcare Conference
01:00am, Tuesday, 25'th Feb 2025
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
01:00am, Thursday, 20'th Feb 2025
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs
12:51pm, Wednesday, 19'th Feb 2025
Argenx recently hit an all-time high ahead of fourth-quarter earnings. Shares are in a flat base with a buy point of 678.21.
